Bossuyt Veerle
Department of Pathology, Yale University, PO Box 208023, 310 Cedar Street, New Haven, CT 06520-8023, USA.
Surg Pathol Clin. 2018 Mar;11(1):213-230. doi: 10.1016/j.path.2017.09.010. Epub 2017 Dec 11.
Standardization of quantification of residual disease in the breast and lymph nodes with routine pathologic macroscopic and microscopic evaluation leads to accurate and reproducible measures of response to neoadjuvant treatment. Multidisciplinary collaboration and correlation of clinical, imaging, gross and microscopic findings is essential. The processing approach to post-neoadjuvant breast cancer surgical specimens and the elements needed in the pathology report are the same regardless of breast cancer subtype or type of neoadjuvant treatment. The residual cancer burden incorporates response in the breast and in the lymph nodes into a score that can be combined with other emerging prognostic factors.
通过常规病理宏观和微观评估对乳腺及淋巴结中的残余病灶进行定量标准化，可得出对新辅助治疗反应的准确且可重复的测量结果。多学科协作以及临床、影像学、大体和微观检查结果的相互关联至关重要。无论乳腺癌亚型或新辅助治疗类型如何，新辅助治疗后乳腺癌手术标本的处理方法及病理报告所需内容均相同。残余癌负荷将乳腺及淋巴结中的反应纳入一个分数，该分数可与其他新出现的预后因素相结合。
